Alchemia's commercial partner stalls synthetic heparin program; possible new partner sought

By Lisa Kerner

Charlotte, N.C., Aug. 28 - Alchemia Ltd. said its commercial partner, Abraxis Pharmaceutical Products (APP), a division of Abraxis BioScience, Inc, suspended process development work in the synthetic heparin program, delaying a planned regulatory filing with the Food and Drug Administration.

APP has not yet decided to continue with the program, according to a news release.

Alchemia said it will transition to a new North American marketing partner should APP drop out of the program.

The company said it is committed to the synthetic heparin program and the market potential of the product, Arixtra, even though sales have not met market expectations.

Results from GlaxoSmithKline's Oasis-5 trial in acute coronary syndrome compared Arixtra with Sanofi-Aventis-marketed Lovenox. Arixtra was found to be much safer than and as effective as Lovenox in preventing death, heart attacks and ischemia, the release said.

Abraxis BioScience is a biopharmaceutical company based in Los Angeles.

Alchemia is a Brisbane, Australia-based drug-discovery company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.